ArticleFrontiers in pharmacology2019
Global Sensitivity Analysis of Ventricular Myocyte Model-Derived Metrics for Proarrhythmic Risk Assessment.
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Improving In Silico Cardiac Safety Prediction by Consensus Averaging of Transmural Ventricular Cell Models.Annals of biomedical engineering · 2026Article
- Drug Proarrhythmic Evaluation in a High Throughput Cardiac New Approach Methodology.bioRxiv : the preprint server for biology · 2026Article
- A multiscale computational model of cardiac electrophysiology for drug-induced pro-arrhythmic risk stratification.Biomedical engineering letters · 2026Article
- Article
- Development ofTranslational and clinical pharmacology · 2024Article
- Proarrhythmic risk assessment of drugs by dVCPT: pharmacometrics & systems pharmacology · 2022Article
- A Quantitative Systems Pharmacology Perspective on the Importance of Parameter Identifiability.Bulletin of mathematical biology · 2022Article
- Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action.Journal of pharmacokinetics and pharmacodynamics · 2022Article
- Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept.European journal of pharmacology · 2021Article
- Circadian Rhythms of Early Afterdepolarizations and Ventricular Arrhythmias in a Cardiomyocyte Model.Biophysical journal · 2021Article
- General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy.Clinical pharmacology and therapeutics · 2020Article
- Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiscale computational models of the heart are being extensively investigated for improved assessment of drug-induced torsades de pointes (TdP) risk, a fatal side effect of many drugs. Model-derived metrics such as action potential duration and net charge carried by ionic currents (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.